We are live on ! Find out more
NVS icon

Novartis

1,306 hedge funds and large institutions have $14.7B invested in Novartis in 2024 Q2 according to their latest regulatory filings, with 133 funds opening new positions, 426 increasing their positions, 488 reducing their positions, and 65 closing their positions.

New
Increased
Maintained
Reduced
Closed

105% more first-time investments, than exits

New positions opened: 133 | Existing positions closed: 65

88% more funds holding in top 10

Funds holding in top 10: 815 (+7)

8% more capital invested

Capital invested by funds: $13.6B → $14.7B (+$1.08B)

4% more funds holding

Funds holding: 1,2531,306 (+53)

0.12% less ownership

Funds ownership: 6.41%6.29% (-0.12%)

11% less call options, than puts

Call options by funds: $219M | Put options by funds: $246M

13% less repeat investments, than reductions

Existing positions increased: 426 | Existing positions reduced: 488

Holders
1,306
Holders Change
+53
Holders Change %
+4.23%
% of All Funds
18.86%
Holding in Top 10
15
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+87.5%
% of All Funds
0.22%
New
133
Increased
426
Reduced
488
Closed
65
Calls
$219M
Puts
$246M
Net Calls
-$26.9M
Net Calls Change
-$21.8M
Name Holding Trade Value Shares
Change
Change in
Stake
Cetera Investment Advisers
126
Cetera Investment Advisers
Illinois
$11.7M +$313K +3,121 +3%
Mirae Asset Global Investments
127
Mirae Asset Global Investments
South Korea
$11.5M +$2.5M +24,954 +30%
Osaic Holdings
128
Osaic Holdings
Arizona
$11.4M +$1.62M +16,095 +18%
Wealth Enhancement Advisory Services
129
Wealth Enhancement Advisory Services
Minnesota
$11.3M -$561K -5,586 -5%
NA
130
NewEdge Advisors
Louisiana
$11.2M -$28.6M -284,568 -73%
Jane Street
131
Jane Street
New York
$11.1M +$7.05M +70,185 +206%
BG
132
Bahl & Gaynor
Ohio
$10.9M -$81.8K -815 -0.8%
EPAM
133
Euro Pacific Asset Management
Puerto Rico
$10.5M -$96.1K -957 -1%
Federated Hermes
134
Federated Hermes
Pennsylvania
$10.4M -$1.23M -12,266 -11%
New York State Common Retirement Fund
135
New York State Common Retirement Fund
New York
$10.2M -$1.32M -13,165 -12%
RWM
136
Ritholtz Wealth Management
New York
$10.1M +$102K +1,015 +1%
AAIM
137
American Assets Investment Management
California
$9.97M
Manulife (Manufacturers Life Insurance)
138
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$9.56M -$3.01K -30 -0%
ZAM
139
Zevin Asset Management
Massachusetts
$9.42M -$230K -2,296 -3%
SIM
140
Seaview Investment Managers
Florida
$9.41M -$48.9K -487 -0.5%
CSIC
141
Clifford Swan Investment Counsel
California
$9.37M -$41.7K -415 -0.5%
MGIA
142
Matthew Goff Investment Advisor
Texas
$9.36M +$333K +3,320 +4%
TBC
143
Tweedy, Browne Co
Connecticut
$9.33M -$185K -1,840 -2%
Baird Financial Group
144
Baird Financial Group
Wisconsin
$9.29M +$567K +5,644 +7%
GF
145
Gabelli Funds
New York
$9.05M -$100K -1,000 -1%
TBA
146
Tower Bridge Advisors
Pennsylvania
$8.87M -$161K -1,606 -2%
UCFA
147
United Capital Financial Advisors
Texas
$8.79M +$356K +3,545 +4%
IHL
148
Investment House LLC
California
$8.78M +$35.1K +350 +0.4%
MCM
149
Mengis Capital Management
Oregon
$8.69M -$220K -2,188 -3%
OCM
150
Osterweis Capital Management
California
$8.64M

NVS Hedge Fund Activity: Q2 2024 in Review

1,306 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q2 2024, worth a combined $14.7B — up 7.9% from $13.6B a quarter earlier.

Buyers outnumbered sellers: 133 funds opened new NVS positions and 65 closed out — a net gain of 68 holders — while 426 added to existing stakes and 488 trimmed.

The largest buyer was Dimensional Fund Advisors, adding an estimated $139M. The largest seller was Mondrian Investment Partners, cutting an estimated $79.6M.

  • 1,306 institutional investors held Novartis (NVS) as of Q2 2024, up from 1,253 in Q1 2024.
  • Funds reported $14.7B of Novartis stock for Q2 2024, up 7.9% quarter-over-quarter.
  • 133 funds opened new Novartis positions in Q2 2024 and 65 closed out, a net change of +68 holders.
  • The largest Novartis buyer in Q2 2024 was Dimensional Fund Advisors, an estimated $139M added.
  • The largest Novartis seller in Q2 2024 was Mondrian Investment Partners, an estimated $79.6M sold.

Based on aggregated 13F filings for Q2 2024.